在基因检测指导下非小细胞肺癌患接受表皮生长因子受体酪氨酸激酶抑制剂治疗临床疗效比较.docVIP

在基因检测指导下非小细胞肺癌患者接受表皮生长因子受体酪氨酸激酶抑制剂治疗临床疗效比较 　　【摘要】 目的：探?病理组织切片和外周血检测基因突变的一致性，不同EGFR敏感突变类型NSCLC患者一线接受EGFR-酪氨酸激酶抑制剂（EGFR-TKIs）治疗的疗效和预后。方法：回顾性分析2016年1月-2017年2月收治的接受EGFR基因检测的晚期NSCLC患者62例的临床资料。比较应用病理组织片和外周血检测基因突变结果的一致性，比较EGFR基因突变组与野生组的临床特征及2种EGFR基因型突变患者EGFR-TKIs治疗的近期疗效和中位无进展生存时间（PFS）。结果：病理组织切片和外周血检测EGFR基因的一致性达0.8（P0.05）。19del组和L858R组的客观有效率（ORR）和疾病控制率（DCR）比较，差异均无统计学意义（P0.05）；而19del组的中位PFS优于L858R组（P中国论文网 /6/viewhtm　　【关键词】 肺癌； 基因检测； 表皮生长因子； 酪氨酸酶抑制剂 　　Clinical Efficacy of EGFR-TKIs Treatment Non-small Cell Lung Cancer under Guidance of Gene Sequencing/WANG Liming，YIN Jun，LIU Shuqin，et al.//Medical Innovation of China，2017，14（32）：005-009 　　【Abstract】 Objective：To investigated the consistency of gene sequencing of histopathologic slide and peripheral blood，and evaluated the curative effect and prognosis of different types of EGFR sensitive mutant NSCLC patients received first-line EGFR-TKIs treatment.Method：The clinical data of 62 cases of advanced NSCLC who received EGFR gene sequencing from January 2016 to February 2017 were retrospectively analyzed.The consistency test gene by histopathologic slide and peripheral blood of mutation results were compared，the clinical features of EGFR gene mutation group and wild group were compared，and short term efficacy and median progression free survival（PFS） of two kinds of EGFR gene mutation in patients treated with EGFR-TKIs were compared.Result：The consistency of detection of EGFR gene in pathological tissue and peripheral blood reached 0.8（P0.05）.The objective response rate（ORR） and disease control rate（DCR） between 19del group and L858R group were compared，the differences were not statistically significant（P0.05）.The median PFS of 19del group was better than that of L858R group（P 　　【Key words】 Lung cancer； Gene sequencing； Epidermal growth factor receptor； Tyrosine kinase inhibitors 　　First-author’s address：Zhenjiang First People’s Hospital，Zhenjiang 212002，China 　　doi：10.3969/j.issn.1674-4985.2017.32.002 　　肺癌是目前我??发病率和死亡